Targeting FoxO1/3a, NF-κB, and mTOR signaling attenuates muscle atrophy in sepsis Authors: Donglin Fu, Min Zhou, Yingxiao Zhang, Pan Cheng, Yue Shu, Qian Xiao, Meng Zhang Published: 2026 ABSTRACT Sepsis frequently leads to skeletal muscle atrophy, but its molecular mechanisms remain unclear. Using a mouse model of cecal ligation and puncture and LPS-treated C2C12 myotubes, we found that sepsis activates autophagy, the ubiquitin-proteasome system (UPS), and calpain pathways, resulting in muscle wasting and functional decline. These changes were linked to upregulated FoxO1/3a and NF-κB signaling and suppressed mTOR activity. Pharmacological inhibition or genetic deletion of key components in these pathways, especially MuRF1, mitigated muscle atrophy and preserved function. Our findings reveal that sepsis-induced muscle loss is driven by coordinated activation of proteolytic systems regulated by the FoxO1/3a, NF-κB, and mTOR signaling pathway, offering potential therapeutic targets.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-026-52665-7. Introduction Sepsis represents a life-threatening syndrome characterized by dysregulated host responses to infection that leads to organ dysfunction and carries substantial mortality risk1. Among its numerous complications, skeletal muscle atrophy (SMA) emerges as a particularly prevalent consequence, affecting approximately 70% of septic patients and contributing to prolonged hospitalization, increased healthcare expenditures, and diminished quality of life2,3. Despite its significant clinical impact, the molecular underpinnings of sepsis-induced SMA remain incompletely characterized, which has hindered the development of targeted therapeutic interventions4. The pathophysiology of sepsis-induced SMA involves complex interactions between inflammatory mediators, metabolic alterations, and proteolytic pathways3. Current evidence indicates that accelerated muscle protein catabolism represents the predominant mechanism underlying sepsis-associated muscle wasting5. The ubiquitin-proteasome system (UPS) has been extensively implicated in this process, with substantial upregulation of the muscle-specific E3 ubiquitin ligases MuRF1 and atrogin-1 consistently observed in skeletal muscle samples from septic patients and experimental models3,6. These enzymes facilitate the targeted degradation of myofibrillar proteins through ubiquitination and subsequent proteasomal processing7.Paralleling UPS activation, the calcium-dependent calpain proteolytic system also demonstrates enhanced activity during sepsis-induced muscle wasting. Calpains primarily target cytoskeletal and membrane-associated proteins, initiating myofibrillar disassembly that facilitates subsequent degradation by other proteolytic systems8. This coordinated action between calpains and the UPS represents a critical axis in sepsis-induced muscle catabolism7. More recently, autophagy has emerged as another significant contributor to sepsis-induced SMA9. This evolutionarily conserved cellular recycling process involves the sequestration of cytoplasmic components within double-membrane vesicles for subsequent lysosomal degradation10. While basal autophagy maintains cellular homeostasis by eliminating damaged organelles and protein aggregates, excessive autophagic activation during sepsis can promote myofibrillar proteolysis and exacerbate muscle wasting9,11. Elevated expression of autophagy markers, including LC3-II and p62, has been documented in muscle specimens from both septic patients and experimental models9,12. Moreover, recent work emphasizes the role of REDD1 as a critical regulator of mTORC1 suppression during sepsis, indirectly modulating autophagy and protein synthesis13. Rapamycin-sensitive mTOR-S6K1 signaling differentially regulates Atrogin-1 and MuRF1 expression, suggesting nuanced roles in sepsis-induced catabolism14. Melatonin was recently shown to attenuate sepsis-induced muscle loss by regulating the PI3K/Akt signaling pathway15. To address these gaps, we conducted a comprehensive investigation using both in vivo and in vitro models of sepsis-induced SMA. We demonstrate that sepsis triggers coordinated activation of autophagy, UPS, and calpain-dependent proteolysis, resulting in profound muscle wasting and functional decline. We further show that these catabolic processes are regulated by a shared signaling axis involving FoxO1/3a, NF-κB, and mTOR. Pharmacological inhibition and genetic ablation of key mediators in each pathway substantially ameliorated muscle atrophy. Notably, muscle-specific deletion of MuRF1 conferred significant structural and functional protection. These findings establish a mechanistic link between upstream signaling pathways and proteolytic effectors in septic muscle, and identify potential therapeutic targets for preventing sepsis-associated muscle loss. Materials and methods Animal model and treatments Male C57BL/6J mice (8–10 weeks old, 20–25 g) were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China, SCXK2016-0006). MuRF1-floxed mice were crossed with MCK-Cre mice (Jackson Laboratory, Stock# 006475) to generate muscle-specific MuRF1 knockout mice. Genotyping was performed by PCR using tail DNA. Mice were housed under specific pathogen-free (SPF) conditions with 12-h light/dark cycles and free access to food and water. All procedures were approved by the Animal Ethics Committee of Chongqing Medical University (IACUC-CQMU-2024-0554). All methods were performed in accordance with relevant institutional and national guidelines and regulations, and the study is reported in compliance with the ARRIVE guidelines. Polymicrobial sepsis was induced by CLP as previously described. Briefly, mice were anesthetized with pentobarbital sodium (50 mg/kg, i.p.; Sigma-Aldrich, P3761) and subjected to midline laparotomy. The cecum was ligated below the ileocecal valve and punctured twice using an 18G needle. A small amount of fecal content was extruded. The cecum was returned, and the abdomen was sutured. Postoperatively, mice received prewarmed saline (1 mL, i.p.) for fluid resuscitation. The following inhibitors were administered intraperitoneally: 3-Methyladenine (3-MA, autophagy inhibitor): Thermo Fisher Scientific, Cat# J64813; Bortezomib (proteasome inhibitor): Selleck Chemicals, Cat# S1013; Calpeptin (calpain inhibitor): MilliporeSigma, Cat# C8999. At the predetermined experimental endpoints, mice were euthanized by an overdose of pentobarbital sodium (150–200 mg/kg, intraperitoneal injection), consistent with AVMA Guidelines for the Euthanasia of Animals (2020) (https://www.avma.org/sites/default/files/2020-02/Guidelines-on-Euthanasia-2020.pdf). Death was confirmed by the absence of respiration and heartbeat and the loss of corneal reflex. Cervical dislocation was performed as a secondary measure when needed to ensure complete euthanasia before tissue collection. Grip strength and treadmill test Forelimb grip strength was measured using a grip strength meter (Columbus Instruments, Cat# 1027CSM). Treadmill endurance was evaluated using a motorized treadmill with increasing speed increments (10–30 cm/s) until exhaustion (Columbus Instruments, Exer 3/6). Histology and CSA measurement Gastrocnemius muscles were fixed in 4% paraformaldehyde (Solarbio, Cat# P1110), embedded in paraffin, sectioned (5 μm), and stained with hematoxylin and eosin (H&E; Beyotime, Cat# C0105). Fiber cross-sectional area (CSA) was quantified using ImageJ software. RNA extraction and quantitative real-time PCR (qRT-PCR) Total RNA was extracted using TRIzol reagent (Invitrogen, Cat# 15596018). First-strand cDNA was synthesized using PrimeScript RT Reagent Kit (Takara, Cat# RR037A). qRT-PCR was conducted with SYBR Green Master Mix (Applied Biosystems, Cat# 4367659) on a LightCycler 480 System (Roche). Primer sequences were listed in the Supplementary Table 1. Western blotting Muscle tissues were homogenized in RIPA buffer with protease/phosphatase inhibitor (Beyotime, Cat# P0013B). Protein concentration was quantified using BCA kit (Thermo Fisher, Cat# 23227). SDS-PAGE was conducted, and proteins were transferred to PVDF membranes (Millipore, Cat# IPVH00010). Secondary HRP-conjugated antibodies were from Jackson ImmunoResearch (Cat# 111-035-003). ECL detection was done using SuperSignal™ West Femto substrate (Thermo Fisher, Cat# 34095). The primary antibodies used in this manuscript were listed in the Supplementary Table 2. Proteasome activity assay Chymotrypsin-like proteasome activity in gastrocnemius muscle lysates was measured using a 20 S Proteasome Activity Assay Kit (Abcam, Cat# ab107921), following the manufacturer’s instructions. Briefly, 50 µg of total protein was incubated with the fluorogenic peptide substrate Suc-LLVY-AMC, which is cleaved by the proteasome to release fluorescent AMC (7-amino-4-methylcoumarin). Fluorescence was measured using a microplate reader (excitation 380 nm, emission 460 nm) at 30-minute intervals for 2 h. Relative proteasome activity was normalized to total protein content. Calpain activity assay Calpain activity in muscle samples was determined using a Calpain Activity Fluorometric Assay Kit (BioVision, Cat# K240-100). Tissue lysates (50–100 µg protein) were incubated with a calpain-specific substrate Ac-LLY-AFC, which releases fluorescent AFC (7-amino-4-trifluoromethyl coumarin) upon cleavage. Fluorescence intensity was recorded at 400 nm (excitation) and 505 nm (emission). Background fluorescence from inhibitor-treated controls was subtracted. Calpain activity was expressed as relative fluorescence units (RFU) per µg of protein. Cell culture and siRNA transfection C2C12 myoblasts were obtained from ATCC (Cat# CRL-1772) and cultured in DMEM (Gibco, Cat# 11965092) with 10% FBS (Gibco, Cat# 10099141). Differentiation into myotubes was induced by switching to 2% horse serum (Gibco, Cat# 16050122). Cells were stimulated with LPS (Sigma-Aldrich, Cat# L2880, 100 ng/mL) for 24 h. For gene knockdown, siRNAs targeting Atg7, MuRF1, atrogin-1, and calpain-1 (Cast) were transfected using Lipofectamine RNAiMAX (Invitrogen, Cat# 13778075). Autophagy flux assessment Cells were treated with chloroquine (Sigma-Aldrich, Cat# C6628) to inhibit lysosomal degradation. LC3-II accumulation and p62 degradation were analyzed via Western blotting. Protein degradation assays Ubiquitinated Protein Accumulation: Total ubiquitinated proteins were assessed by Western blot using an anti-ubiquitin antibody (Cell Signaling Technology, Cat# 3936). Increased accumulation of ubiquitinated proteins reflects enhanced proteasomal targeting and degradation. Protein synthesis assay Muscle protein synthesis was evaluated using the SUnSET (Surface Sensing of Translation) method based on puromycin incorporation. Mice were injected intraperitoneally with puromycin (0.04 µmol/g body weight; Millipore, Cat# MABE343) 30 min before euthanasia. Gastrocnemius muscles were collected, homogenized in RIPA buffer, and subjected to Western blot analysis using an anti-puromycin antibody (Millipore, Cat# MABE343) to detect puromycin-labeled nascent polypeptides. The relative intensity of puromycin-labeled bands reflected the rate of de novo protein synthesis. Statistical analysis Data are presented as mean ± SEM. Statistical analyses were performed using GraphPad Prism 9. Comparisons between two groups were conducted using unpaired two-tailed Student’s t-test. Comparisons among multiple groups were analyzed using one-way ANOVA followed by Tukey’s multiple comparisons test. A value of p < 0.05 was considered statistically significant. Statistical significance is indicated as follows: *p < 0.05, **p < 0.01, ***p < 0.001. Results LPS induces muscle atrophy via activation of autophagy, proteasome, and calpain pathways To investigate the mechanisms of skeletal muscle atrophy, we employed an LPS-induced model and examined gastrocnemius muscle morphology along with key proteolytic markers. H&E staining revealed significant myofiber atrophy in LPS-treated mice compared to controls (Fig. 1A). Quantification of myotube diameter confirmed a marked decrease following LPS stimulation (Fig. 1B). Fig. 1LPS induces myotube atrophy through activation of proteasomal, autophagic, and calpain-mediated proteolytic pathways. (A) Representative H&E-stained images of gastrocnemius muscle from control and LPS-induced mice showing significant atrophy after LPS treatment compared to control (scale bar: 100 μm). (B) Quantification of myotube diameter shows that LPS significantly reduces myotube size. Data = mean ± SEM; n = 3 mice per group. *p < 0.05, ***p < 0.001. (C) Western blot analysis of MuRF1, Atrogin-1, and LC3 expression in gastrocnemius muscle tissues from LPS-induced mice, with or without treatment using 3-MA, bortezomib, calpeptin, or siRNA targeting Atg7, MuRF1, and Cast. (D–F) Quantification of Atrogin-1, MuRF1, and LC3-II/LC3-I ratio across the indicated groups. LPS increased expression of all markers, which was significantly attenuated by pharmacological or genetic inhibition of corresponding pathways. Data = mean ± SEM; n = 4 independent biological experiments. *p < 0.05, **p < 0.01, ***p < 0.001. LPS induces myotube atrophy through activation of proteasomal, autophagic, and calpain-mediated proteolytic pathways. (A) Representative H&E-stained images of gastrocnemius muscle from control and LPS-induced mice showing significant atrophy after LPS treatment compared to control (scale bar: 100 μm). (B) Quantification of myotube diameter shows that LPS significantly reduces myotube size. Data = mean ± SEM; n = 3 mice per group. *p < 0.05, ***p < 0.001. (C) Western blot analysis of MuRF1, Atrogin-1, and LC3 expression in gastrocnemius muscle tissues from LPS-induced mice, with or without treatment using 3-MA, bortezomib, calpeptin, or siRNA targeting Atg7, MuRF1, and Cast. (D–F) Quantification of Atrogin-1, MuRF1, and LC3-II/LC3-I ratio across the indicated groups. LPS increased expression of all markers, which was significantly attenuated by pharmacological or genetic inhibition of corresponding pathways. Data = mean ± SEM; n = 4 independent biological experiments. *p < 0.05, **p < 0.01, ***p < 0.001. Western blot analysis demonstrated elevated levels of MuRF1, Atrogin-1, and LC3-II/LC3-I ratio in LPS-treated muscle tissues, indicating activation of the ubiquitin-proteasome and autophagic pathways (Fig. 1C–F). These increases were significantly attenuated by treatment with 3-MA (autophagy inhibitor), bortezomib (proteasome inhibitor), calpeptin (calpain inhibitor), or siRNA-mediated knockdown of Atg7, MuRF1, and Cast. Collectively, these findings support that LPS-induced muscle atrophy is mediated through activation of proteasomal, autophagic, and calpain-dependent proteolytic systems. Inhibition of autophagy and proteasome pathways attenuates LPS-induced muscle wasting We next assessed the therapeutic impact of pathway-specific inhibitors on LPS-induced muscle damage. Treatment with 3-MA, bortezomib, or calpeptin significantly restored muscle fiber diameter compared to LPS-only mice (Fig. 2A–C). Similarly, genetic deletion of Atg1 or Atg7 rescued myotube diameter loss under LPS challenge (Fig. 2D–E). Fig. 2Inhibition of autophagy and proteasome pathways attenuates LPS-induced myotube atrophy. (A–C) Quantification of muscle fiber diameter in gastrocnemius muscles from LPS-induced mice shows that treatment with 3-MA (autophagy inhibitor), bortezomib (proteasome inhibitor), or calpeptin (calpain inhibitor) partially alleviates LPS-induced muscle atrophy. Data = mean ± SEM; n = 3 mice per group. *p < 0.05, ***p < 0.001. (D, E) Myotube diameter was measured in Atg1- and Atg7-knockout mice under LPS conditions. Data = mean ± SEM; n = 3 mice per group. ***p < 0.001. Inhibition of autophagy and proteasome pathways attenuates LPS-induced myotube atrophy. (A–C) Quantification of muscle fiber diameter in gastrocnemius muscles from LPS-induced mice shows that treatment with 3-MA (autophagy inhibitor), bortezomib (proteasome inhibitor), or calpeptin (calpain inhibitor) partially alleviates LPS-induced muscle atrophy. Data = mean ± SEM; n = 3 mice per group. *p < 0.05, ***p < 0.001. (D, E) Myotube diameter was measured in Atg1- and Atg7-knockout mice under LPS conditions. Data = mean ± SEM; n = 3 mice per group. ***p < 0.001. These results indicate that both autophagy and proteasome pathways contribute significantly to LPS-induced muscle degradation. Inhibition of autophagy and proteasome pathways rescues muscle integrity in CLP-induced septic mice To further validate the contribution of autophagy and proteasome pathways in vivo under septic conditions, we employed the CLP-induced sepsis model to evaluate how blocking autophagy, proteasome pathways impacts muscle proteolysis. Western blot analysis showed a marked increase in p62 accumulation in the gastrocnemius muscle of CLP mice, which was significantly reduced by treatment with the autophagy inhibitor 3-MA, but not by bortezomib or calpeptin (Fig. 3A, B). Fig. 3Pharmacological inhibition of proteasomal and autophagy pathways alleviates sepsis-induced muscle proteolysis and atrophy. (A, B) Representative Western blots showing p62 protein levels in gastrocnemius muscles from sham, CLP + vehicle, and CLP mice treated with 3-MA (autophagy inhibitor), bortezomib (proteasome inhibitor), or calpeptin (calpain inhibitor). GAPDH served as a loading control. Quantification of p62 protein expression normalized to GAPDH. Data = mean ± SEM; n = 4 mice per group. ***p < 0.001. (C) Proteasome activity in gastrocnemius muscle homogenates measured using a fluorometric proteasome assay kit. Data = mean ± SEM; n = 4 mice per group. **p < 0.01, ***p < 0.001. (D) Calpain activity assessed using a calpain activity assay kit. Data shown as relative activity (arbitrary units). Data = mean ± SEM; n = 4 mice per group. *p < 0.05, **p < 0.01, ***p < 0.001. (E) Autophagy flux measured by LC3 turnover assay following lysosomal inhibition (chloroquine), expressed as LC3-II/LC3-I ratio. Data = mean ± SEM; n = 4 mice per group. **p < 0.01, ***p < 0.001. (F) H&E staining of gastrocnemius muscle sections from each treatment group. CLP induced muscle fiber atrophy and architectural disruption, which was partially rescued by pharmacological treatments (scale bar: 100 μm). (G, H) Quantification of fiber diameter and cross-sectional area (CSA) confirmed significant improvement from each treatment group. Data = mean ± SEM; n = 4 mice per group. **p < 0.01, ***p < 0.001. Pharmacological inhibition of proteasomal and autophagy pathways alleviates sepsis-induced muscle proteolysis and atrophy. (A, B) Representative Western blots showing p62 protein levels in gastrocnemius muscles from sham, CLP + vehicle, and CLP mice treated with 3-MA (autophagy inhibitor), bortezomib (proteasome inhibitor), or calpeptin (calpain inhibitor). GAPDH served as a loading control. Quantification of p62 protein expression normalized to GAPDH. Data = mean ± SEM; n = 4 mice per group. ***p < 0.001. (C) Proteasome activity in gastrocnemius muscle homogenates measured using a fluorometric proteasome assay kit. Data = mean ± SEM; n = 4 mice per group. **p < 0.01, ***p < 0.001. (D) Calpain activity assessed using a calpain activity assay kit. Data shown as relative activity (arbitrary units). Data = mean ± SEM; n = 4 mice per group. *p < 0.05, **p < 0.01, ***p < 0.001. (E) Autophagy flux measured by LC3 turnover assay following lysosomal inhibition (chloroquine), expressed as LC3-II/LC3-I ratio. Data = mean ± SEM; n = 4 mice per group. **p < 0.01, ***p < 0.001. (F) H&E staining of gastrocnemius muscle sections from each treatment group. CLP induced muscle fiber atrophy and architectural disruption, which was partially rescued by pharmacological treatments (scale bar: 100 μm). (G, H) Quantification of fiber diameter and cross-sectional area (CSA) confirmed significant improvement from each treatment group. Data = mean ± SEM; n = 4 mice per group. **p < 0.01, ***p < 0.001. Enzymatic assays showed that CLP-induced increases in proteasome activity, calpain activity, and autophagic flux were all significantly attenuated by inhibition (Fig. 3C–E). Histological examination demonstrated partial rescue of muscle fiber structure by each inhibitor (Fig. 3F), with quantification of fiber diameter and CSA confirming protective effects (Fig. 3G–H). Sepsis activates activates FoxO, NF-κB, MAPK, and mTOR signaling pathways which are reversed by autophagy and proteasome inhibition CLP-induced sepsis resulted in significant upregulation of FoxO1 and FoxO3a mRNA expression in gastrocnemius muscle (Fig. 4A–B). Western blot analysis revealed enhanced phosphorylation of FoxO1, NF-κB, MAPK, and mTOR, indicating activation of inflammatory and catabolic signaling pathways (Fig. 4C–G). Fig. 4Sepsis activates FoxO, NF-κB, MAPK, and mTOR signaling pathways, which are suppressed by autophagy and proteasome inhibition. (A, B) Quantitative PCR analysis revealed significantly elevated mRNA levels of FoxO1 and FoxO3a in gastrocnemius muscles of septic mice (CLP group) compared to sham controls. Data = mean ± SEM; n = 3 mice per group. ***p < 0.001. (C) Representative Western blot images showing the expression of phosphorylated and total FoxO1, FoxO3a, NF-κB p-p65, NF-κB p65, p-p38 MAPK, p38 MAPK, mTOR and p- mTOR in gastrocnemius tissues from sham-operated, CLP-induced septic mice, and CLP mice treated with pharmacological inhibitors—3-MA (autophagy inhibitor), bortezomib (proteasome inhibitor), or calpeptin (calpain inhibitor). (D–G) quantification demonstrated that pharmacological inhibition of autophagy (3-MA) and the proteasome pathway (bortezomib) significantly reduced phosphorylation levels of FoxO1 (D), NF-κB p65 (E), p38 MAPK (F), and mTOR (G), compared to the CLP group. Data = mean ± SEM; n = 4 mice per group. **p < 0.01, ***p < 0.001. Sepsis activates FoxO, NF-κB, MAPK, and mTOR signaling pathways, which are suppressed by autophagy and proteasome inhibition. (A, B) Quantitative PCR analysis revealed significantly elevated mRNA levels of FoxO1 and FoxO3a in gastrocnemius muscles of septic mice (CLP group) compared to sham controls. Data = mean ± SEM; n = 3 mice per group. ***p < 0.001. (C) Representative Western blot images showing the expression of phosphorylated and total FoxO1, FoxO3a, NF-κB p-p65, NF-κB p65, p-p38 MAPK, p38 MAPK, mTOR and p- mTOR in gastrocnemius tissues from sham-operated, CLP-induced septic mice, and CLP mice treated with pharmacological inhibitors—3-MA (autophagy inhibitor), bortezomib (proteasome inhibitor), or calpeptin (calpain inhibitor). (D–G) quantification demonstrated that pharmacological inhibition of autophagy (3-MA) and the proteasome pathway (bortezomib) significantly reduced phosphorylation levels of FoxO1 (D), NF-κB p65 (E), p38 MAPK (F), and mTOR (G), compared to the CLP group. Data = mean ± SEM; n = 4 mice per group. **p < 0.01, ***p < 0.001. Notably, inhibition with 3-MA or bortezomib, and calpeptin, significantly suppressed phosphorylation of FoxO1, NF-κB, MAPK, and mTOR (Fig. 4C–G), suggesting that autophagy and proteasome pathways regulate these catabolic signals in septic muscle. MuRF1 knockout preserves muscle mass and function under septic stress Western blot confirmed increased MuRF1 expression in CLP-induced muscle (Fig. 5A, B). LPS-treated MuRF1 KO myotubes displayed greater diameters than WT controls, indicating protection from catabolic insults (Fig. 5C). Atrogin-1 expression was markedly decreased in KO mice (Fig. 5D, E), suggesting suppressed proteasomal activity. Fig. 5MuRF1 knockout attenuates sepsis-induced muscle atrophy by suppressing proteolysis and autophagy and enhancing protein synthesis. (A, B) Western blot and quantification show that MuRF1 protein expression is significantly elevated in gastrocnemius muscle of CLP-induced mice, Data = mean ± SEM; n = 3 mice per group. **p < 0.01. (C) Quantification of myofiber diameter in WT and MuRF1 knockout (KO) mice under LPS treatment, Data = mean ± SEM; n = 3 mice per group. *p < 0.05. (D, E) Representative Western blot and quantification of Atrogin-1 expression in WT and MuRF1 KO gastrocnemius muscle, Data = mean ± SEM; n = 3 mice per group. ***p < 0.001. (F–H) Functional tests show that MuRF1 KO mice have improved grip strength, tensile force, and specific force compared to WT under septic conditions. Data = mean ± SEM; n = 3 mice per group. **p < 0.01, ***p < 0.001. (I) Representative H&E-stained gastrocnemius muscle sections from control and MuRF1 KO septic mice. KO mice display preserved muscle architecture and reduced fiber damage. Scale bar = 100 μm. (J–K) Quantification of muscle fiber diameter and cross-sectional area (CSA) confirms structural preservation in MuRF1 KO mice, Data = mean ± SEM; n = 4 mice per group. **p < 0.01, ***p < 0.001. (M, N) Metabolic assays show that MuRF1 deficiency leads to a significant reduction in protein degradation and an increase in protein synthesis under septic stress, Data = mean ± SEM; n = 3 mice per group. **p < 0.01, ***p < 0.001. MuRF1 knockout attenuates sepsis-induced muscle atrophy by suppressing proteolysis and autophagy and enhancing protein synthesis. (A, B) Western blot and quantification show that MuRF1 protein expression is significantly elevated in gastrocnemius muscle of CLP-induced mice, Data = mean ± SEM; n = 3 mice per group. **p < 0.01. (C) Quantification of myofiber diameter in WT and MuRF1 knockout (KO) mice under LPS treatment, Data = mean ± SEM; n = 3 mice per group. *p < 0.05. (D, E) Representative Western blot and quantification of Atrogin-1 expression in WT and MuRF1 KO gastrocnemius muscle, Data = mean ± SEM; n = 3 mice per group. ***p < 0.001. (F–H) Functional tests show that MuRF1 KO mice have improved grip strength, tensile force, and specific force compared to WT under septic conditions. Data = mean ± SEM; n = 3 mice per group. **p < 0.01, ***p < 0.001. (I) Representative H&E-stained gastrocnemius muscle sections from control and MuRF1 KO septic mice. KO mice display preserved muscle architecture and reduced fiber damage. Scale bar = 100 μm. (J–K) Quantification of muscle fiber diameter and cross-sectional area (CSA) confirms structural preservation in MuRF1 KO mice, Data = mean ± SEM; n = 4 mice per group. **p < 0.01, ***p < 0.001. (M, N) Metabolic assays show that MuRF1 deficiency leads to a significant reduction in protein degradation and an increase in protein synthesis under septic stress, Data = mean ± SEM; n = 3 mice per group. **p < 0.01, ***p < 0.001. Functional measurements revealed improved grip strength, tensile force, and specific force in KO mice under CLP-induced septic conditions (Fig. 5F–H). Histological analysis further demonstrated increased fiber diameter and CSA in MuRF1-deficient mice (Fig. 5I–K). Finally, MuRF1 knockout also led to reduced protein degradation and enhanced protein synthesis under sepsis (Fig. 5M–N), supporting its key role in regulating muscle proteostasis during inflammation. Discussion This study demonstrates that coordinated activation of autophagy, the ubiquitin-proteasome system (UPS), and calpain proteolysis drives skeletal muscle wasting and dysfunction during sepsis. Targeted inhibition of these pathways, via pharmacological or genetic approaches, significantly preserved muscle mass and strength, underscoring their therapeutic relevance. Our results confirm and extend previous findings that autophagy and UPS contribute to muscle catabolism in sepsis. Notably, suppression of autophagy by 3-MA or Atg7 knockout, and blockade of MuRF1, atrogin-1, or calpains, each provided substantial protection. These findings suggest that simultaneous regulation of multiple degradation systems may be necessary to prevent muscle loss. Previous studies also demonstrated that excessive MuRF1 expression may be glucocorticoid-driven and independent of the Akt/FoxO1 pathway under pharmacological stress16,17, suggesting intrinsic tissue-level regulation. We identified that sepsis alters key regulatory signals, including activation of FoxO1/3a and NF-κB and inhibition of mTOR, which modulate atrophy-related gene expression. Inhibiting proteolytic pathways partially reversed these changes, indicating interplay between signaling pathways and downstream effectors. Smad3 has also been implicated in promoting Atrogin-1 expression while inhibiting mTOR signaling, indicating possible upstream integration of TGF-β signals with FoxO-mTOR networks18. The Akt/FoxO pathway appears to mediate sepsis-induced metabolic dysfunction, including impaired pyruvate oxidation and lactate accumulation, which exacerbate muscle wasting19. our findings demonstrate that co-inhibition of FoxO1/3a, NF-κB, and mTOR-linked proteolysis confers robust protection against sepsis-induced muscle wasting. Emerging evidence implicates phospholipase D and phosphatidic acid in regulating muscle mass via mTORC1, offering novel pharmacological targets for muscle preservation20. We also show that sepsis-induced muscle atrophy is driven by convergent proteolytic pathways regulated by FoxO1/3a, NF-κB, and mTOR signaling. Targeting these mechanisms could offer new strategies to preserve muscle mass and improve outcomes in septic patients. Although NF-κB and mTOR are established regulators of inflammatory and metabolic signaling, the present findings extend their pathophysiological relevance to sepsis-induced skeletal muscle atrophy and further place FoxO1/3a within this broader regulatory context. The significance of this study lies in showing that septic muscle wasting is associated not with activation of a single catabolic pathway, but with coordinated changes in FoxO1/3a-, NF-κB-, and mTOR-related signaling accompanied by the activation of several downstream proteolytic systems, including autophagy, the ubiquitin–proteasome system, and calpain-mediated proteolysis. This broader framework helps explain why muscle wasting in sepsis is often severe and multifactorial, reflecting the combined effects of inflammatory activation, disturbed proteostasis, and reduced functional integrity. In addition, the protective effects observed after pharmacological or genetic targeting of key components suggest that these pathways are not merely correlative markers, but functionally relevant contributors to the atrophic process. From a translational perspective, these findings support the concept that therapeutic approaches aimed at preserving muscle mass and function in sepsis may need to target network-level dysregulation rather than any single effector pathway in isolation. Although our data support the involvement of FoxO1/3a-, NF-κB-, and mTOR-related signaling in sepsis-induced muscle atrophy, they do not fully establish the direct causal and hierarchical relationships among these pathways. The current findings primarily demonstrate concurrent changes in these signaling components in parallel with activation of downstream proteolytic systems, including autophagy, the ubiquitin–proteasome system, and calpain-mediated proteolysis. Therefore, the present results are more consistent with coordinated pathway involvement than with a definitive linear regulatory axis. It also remains possible that these signaling pathways respond in parallel to septic stress rather than functioning through a strict upstream–downstream cascade. Further mechanistic studies incorporating pathway-specific activation or inhibition, rescue experiments, and epistasis-based analyses will be necessary to clarify the precise relationships among these pathways. Another limitation is that all in vivo experiments were conducted in young male C57BL/6J mice. Young male animals were selected in this initial mechanistic study to reduce variability related to estrous cycling and age-associated physiological heterogeneity; however, this design limits the generalizability of our findings. Given the known sex- and age-dependent differences in immune response, hormonal regulation, muscle metabolism, and sepsis outcomes, caution is warranted when extrapolating these findings to female or aged animals. Validation in female and aged sepsis models will therefore be necessary to determine the broader applicability of our findings. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1 Supplementary Material 2 Supplementary Material 2